apo-rasagiline tablet
apotex inc - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors
apo-rasagiline tablet
apotex inc - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors
teva-rasagiline tablet
teva canada limited - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors
teva-rasagiline tablet
teva canada limited - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors
mint-rasagiline tablet
mint pharmaceuticals inc - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg
mint-rasagiline tablet
mint pharmaceuticals inc - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg
ag-rasagiline tablet
angita pharma inc. - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors
ag-rasagiline tablet
angita pharma inc. - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors
rasagiline tablet
teva pharmaceuticals usa, inc. - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline 0.5 mg - rasagiline tablets are indicated for the treatment of parkinson’s disease (pd). rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)] . at least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with these medications. rasagiline is contraindicated for use with st. john’s wort and with cyclobenzaprine. rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. risk summary there are no adequate data on the developmental risks associated with the use of rasagiline in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinically. when administered to pregnant animals in combin
rasagiline tablet
ascend laboratories, llc - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline 0.5 mg - rasagiline tablets are indicated for the treatment of parkinson's disease (pd) rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions ( 5.2 )]. at least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with these medications. rasagiline is contraindicated for use with st. john’s wort and with cyclobenzaprine. rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. risk summary there are no adequate data on the developmental risks associated with the use of rasagiline in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinically. when administered to pregnant animals in comb